NCT00109174 MRS Measurement of Glutamate and GABA Metabolism in Brain
| NCT ID | NCT00109174 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Mental Health (NIMH) |
| Condition | Normal Physiology |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2006-09-06 |
| Primary Completion | 2030-01-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2006-09-06 with a primary completion date of 2030-01-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of \[13\]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).
Eligibility Criteria
* INCLUSION CRITERIA: * 18-65 years of age * Able to give written informed consent * Healthy based on medical history and physical exam * Enrolled in Protocol 01-M-0254 or Protocol 17-M-0181 EXCLUSION CRITERIA: * Any current Axis 1 diagnosis * Clinically significant laboratory abnormalities * Positive HIV test * Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan. * History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury * Prescription psychotropic medication; drug free less than 8 weeks (anticholinergics, benzodiazepine, fluoxetine, antipsychotics, and anticonvulsants) * Serious medical illness as determined from H\&P or laboratory testing including Diabetes * Inability to lie flat on camera bed for about two and a half hours * Pregnant or breastfeeding * Current substance use disorder based on DSM-5 * NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
Contact & Investigator
Li An, Ph.D.
PRINCIPAL INVESTIGATOR
National Institute of Mental Health (NIMH)
Frequently Asked Questions
Who can join the NCT00109174 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Normal Physiology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00109174 currently recruiting?
Yes, NCT00109174 is actively recruiting participants. Contact the research team at johnsonchri@mail.nih.gov for enrollment information.
Where is the NCT00109174 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00109174 clinical trial?
NCT00109174 is sponsored by National Institute of Mental Health (NIMH). The principal investigator is Li An, Ph.D. at National Institute of Mental Health (NIMH). The trial plans to enroll 200 participants.